MedTrace Logo

Long-Term Immunogenicity of Envacgen® in Children

NCT07568522 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2026-05-05

No results posted yet for this study

Summary

This study is designed to evaluate the long-term antibody titers of Envacgen® approximately 6 years after the first vaccination dose in participants who were aged 2 months to \<6 years at the time of enrollment in the CT-EV-31s study.

Conditions

  • Enterovirus 71 Human

Interventions

BIOLOGICAL

EV71 vaccine

EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-31s study

Sponsors & Collaborators

  • Medigen Vaccine Biologics Corp.

    lead INDUSTRY

Principal Investigators

  • Li-Min Huang, M.D., Ph.D. · National Taiwan University Hospital

  • Nan-Chang Chiu, M.D. · Mackay Memorial Hospital

  • Cheng-Hsun Chiu, M.D., Ph.D. · Chang Gang Memorial Hospital, LinKou

  • Chien-Yu Lin, M.D., Ph.D. · Mackay Memorial Hospital, HsinChu

Eligibility

Min Age
6 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2026-02-16
Completion
2026-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07568522 on ClinicalTrials.gov